Long-term follow-up of patients with metastatic breast cancer: Results of a retrospective, single-center analysis from 2000 to 2005

Anti-Cancer Drugs

Volumn 22, Issue 9, 2011, Pages 933-939

  Geiger, Sandra ^a   Cnossen, Jitske Alida ^a   Horster, Sophia ^b   Digioia, Dorit ^a   Heinemann, Volker ^a   Stemmler, Hans Joachim ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

chemotherapy; hormonal therapy; metastatic breast cancer; survival; therapy sequences

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SKIN METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EPIDEMIOLOGIC STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052439246     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834860af     Document Type: Article

References (45)

1. Muss HB, Case LD, Richards F II, White DR, Cooper MR, Cruz JM, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: the Piedmont Oncology Association. N Engl J Med 1991; 325:1342-1348
2. Norton L. Metastatic breast cancer: length and quality of life. N Engl J Med 1991; 325:1370-1371
3. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004; 22:3302-3308 (Pubitemid 41103686)
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2 N Engl J Med 2001; 344:783-792 (Pubitemid 32222155)
5. Slamon D. Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs 2000; 4:24-29
6. Crown J, Dieras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol 2002; 3:719-727 (Pubitemid 35446740)
7. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593 (Pubitemid 37328925)
8. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colonystimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558-3585
9. Manglani HH, Marco RA, Picciolo A, Healey JH. Orthopedic emergencies in cancer patients. Semin Oncol 2000; 27:299-310. (Pubitemid 30395163)
10. Vogl TJ, Weinhold N, Muller P, Mack M, Scholz W, Philipp C, et al. MRcontrolled laser-induced thermotherapy (LITT) of liver metastases: clinical evaluation. Rontgenpraxis 1996; 49:161-168 (Pubitemid 26253730)
11. Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the 'test-of-time approach'. Cancer 2003; 97:3027-3035 (Pubitemid 36676257)
12. Maksan SM, Lehnert T, Bastert G, Herfarth C. Curative liver resection for metastatic breast cancer. Eur J Surg Oncol 2000; 26:209-212 (Pubitemid 30319223)
13. Friedrich M, Cordes T, Fersis N, Hornung D, Loning M, Diedrich K, et al. Metastatic breast cancer: options for metastasectomy. Zentralbl Gynakol 2005; 127:222-227 (Pubitemid 41117041)
14. Gunabushanam G, Sharma S, Thulkar S, Srivastava DN, Rath GK, Julka PK, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol 2007; 18:67-72 (Pubitemid 46616669)
15. Bangash AK, Atassi B, Kaklamani V, Rhee TK, Yu M, Lewandowski RJ, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 2007; 18:621-628 (Pubitemid 46661173)
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. NJ Am Stat Assoc 1959; 53:457-481
17. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992; 3:452-456
18. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al.; 304 Study Group. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17:1413-1424 (Pubitemid 29220847)
19. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, et al.; Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83:1142-1152 (Pubitemid 28419067)
20. Helmberger T, Holzknecht N, Schopf U, Kulinna C, Rau H, Stabler A, et al. Radiofrequency ablation of liver metastases: technique and initial results. Radiologe 2001; 41:69-76 (Pubitemid 32151044)
21. Abrial C, Leheurteur M, Cabrespine A, Mouret-Reynier MA, Durando X, Ferriere JP, et al. Does survival increase in metastatic breast cancer with recently available anticancer drugs? Oncol Res 2006; 15:431-439
22. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for her2 overexpressing metastatic breast cancer (mbc).Onkologie 2005; 28:582-586 (Pubitemid 41513144)
23. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742-1750. (Pubitemid 41437440)
24. Falkson G, Holcroft C, Gelman RS, Tormey DC, Wolter JM, Cummings FJ. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13:1453-1458
25. Falkson G, Tormey DC, Carey P,Witte R, Falkson HC. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer 1991; 27:973-977
26. Miao PT, Tong ZS, Hao CF, Zhang L. Prognostic analysis of patients with metastatic triple-negative breast cancer: a report of 120 cases. Zhonghua Yi Xue Za Zhi 2010; 90:2848-2851
27. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205-214
28. Evrard S, Becouarn Y, Fonck M, Brunet R, Mathoulin-Pelissier S, Picot V. Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination. Eur J Surg Oncol 2004; 30:399-406 (Pubitemid 38528924)
29. Navarra G, Ayav A, Weber JC, Jensen SL, Smadga C, Nicholls JP, et al. Short- and-long term results of intraoperative radiofrequency ablation of liver metastases. Int J Colorectal Dis 2005; 20:521-528 (Pubitemid 41479019)
30. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003; 90:1240-1243 (Pubitemid 37330428)
31. Vlastos G, Smith DL, Singletary SE, Mirza NQ, Tuttle TM, Popat RJ, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 2004; 11:869-874
32. Pereira PL. Actual role of radiofrequency ablation of liver metastases. Eur Radiol 2007; 17:2062-2070. (Pubitemid 47097464)
33. Choi BS, Robins HI. Primary disease resection in metastatic breast cancer improves survival. J Clin Oncol 2007; 25:603-604 Author reply 604 (Pubitemid 350002973)
34. De Boer RH, Smith IE, Sacks NP. Long-term survival after hepatic resection for metastatic breast cancer: a case report. Eur J Cancer 1998; 34:1815 (Pubitemid 28474243)
35. Ernst I, Lucking PS, Eickmeyer F, Beckers E, Roth A, Schneid S, et al. Stereotactic body radiotherapy (sbrt): an overview under special consideration of SBRT and LITT in the therapy of liver metastases. Zentralbl Gynakol 2006; 128:71-75
36. Figueras J, Llado L. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the 'test-of-time' approach. Cancer 2003; 98:2303-2304 author reply 2304-2305
37. Frezza EE,Wachtel MS, Barragan B, Chiriva-Internati M, Cobos E. The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A 2007; 17:282-284 (Pubitemid 46981775)
38. Gomez Senent S, Gomez Raposo C, Mancenido Marcos N, Martin Chavarri S, Carrion Alonso G, Olveira Martin A, et al. Radiofrequency ablation for hepatocellular carcinoma and liver metastases: experience in hospital La Paz. Clin Transl Oncol 2006; 8:688-691
39. Heinemann V, Kahlert S, Stemmler HJ. Multimodality treatment concepts for metastatic breast cancer. Internist (Berl) 2010; 51:1358-1365
40. Isbert C, Ritz JP, Roggan A, Schuppan D, Ajubi N, Buhr HJ, et al. Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med 2007; 39:42-50. (Pubitemid 46239799)
41. Jakobs TF, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008; 19:683-690.
42. Jakobs TF, Hoffmann RT, Schrader A, Stemmler HJ, Trumm C, Lubienski A, et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 2009; 32:38-46
43. Kogure K, Sakurai T, Tsuzuki Y, Ishizaki M, Nemoto M, Fukusato T, et al. Long-term survival after hepatectomy for large metastatic breast cancer: a case report. Hepatogastroenterology 2003; 50:827-829 (Pubitemid 36613415)
44. Puls R, Stroszczynski C, Gaffke G, Hosten N, Felix R, Speck U. Laserinduced thermotherapy (LITT) of liver metastases: MR-guided percutaneous insertion of an MRI-compatible irrigated microcatheter system using a closed high-field unit. J Magn Reson Imaging 2003; 17:663-670. (Pubitemid 36665870)
45. Vogl TJ, Weinhold N, Muller P, Phillip C, Roggan A, Mack MG, et al. Early clinical experiences with MR-guided laser-induced thermotherapy (LITT) of liver metastases in preoperative care. RoFo 1996; 164:413-421